Opinion: PARP inhibitors in cancer-what do we still need to know?
Loading...
Embargo End Date
ICR Authors
Authors
Wicks, AJ
Krastev, DB
Pettitt, SJ
Tutt, ANJ
Lord, CJ
Krastev, DB
Pettitt, SJ
Tutt, ANJ
Lord, CJ
Document Type
Journal Article
Date
2022-07-01
Date Accepted
2022-07-01
Abstract
PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We discuss the need to refine the current repertoire of clinical-grade companion biomarkers to be used with PARPi, so that patient stratification can be improved, the early emergence of drug resistance can be detected and dose-limiting toxicity can be predicted. We also highlight current thoughts about how PARPi resistance might be treated.
Citation
Open Biology, 2022, 12 (7), pp. 220118 -
Source Title
Open Biology
Publisher
The Royal Society
ISSN
2046-2441
eISSN
2046-2441
2046-2441
2046-2441
Collections
Research Team
Gene Function